Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of copanlisib and how well it
works when given together with eribulin in treating patients with triple negative breast
cancer that has spread to other places in the body (advanced stage). Copanlisib stops the
growth of a protein called PI3K, which is often changed in tumor cells and causes resistance
to treatment. Chemotherapy drugs, such as eribulin, work in different ways to stop the growth
of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Giving copanlisib and eribulin may work better in treating advanced
stage triple negative breast cancer compared to eribulin alone.